Your browser is no longer supported. Please, upgrade your browser.
DEPO Depomed, Inc. daily Stock Chart
Depomed, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own0.60% Shs Outstand61.87M Perf Week1.01%
Market Cap1.18B Forward P/E11.85 EPS next Y1.60 Insider Trans-15.48% Shs Float60.35M Perf Month-0.63%
Income-85.00M PEG- EPS next Q0.26 Inst Own- Short Float21.42% Perf Quarter8.32%
Sales415.30M P/S2.83 EPS this Y-161.40% Inst Trans5.15% Short Ratio9.25 Perf Half Y14.05%
Book/sh4.92 P/B3.86 EPS next Y34.03% ROA-6.30% Target Price23.73 Perf Year-42.16%
Cash/sh3.11 P/C6.11 EPS next 5Y18.00% ROE-26.10% 52W Range12.25 - 33.25 Perf YTD4.80%
Dividend- P/FCF9.16 EPS past 5Y-6.93% ROI-0.30% 52W High-42.86% Beta1.17
Dividend %- Quick Ratio0.90 Sales past 5Y33.50% Gross Margin78.70% 52W Low55.10% ATR0.79
Employees494 Current Ratio0.90 Sales Q/Q225.50% Oper. Margin-10.80% RSI (14)46.99 Volatility3.93% 4.26%
OptionableYes Debt/Eq2.72 EPS Q/Q-75.90% Profit Margin-20.50% Rel Volume0.42 Prev Close19.24
ShortableYes LT Debt/Eq2.39 EarningsJul 28 AMC Payout- Avg Volume1.40M Price19.00
Recom2.10 SMA20-0.95% SMA50-2.39% SMA2007.99% Volume586,800 Change-1.25%
Jul-07-16Downgrade UBS Buy → Neutral $20
May-27-16Reiterated Mizuho Buy $19 → $23
May-09-16Upgrade Mizuho Neutral → Buy $19
Apr-11-16Reiterated Mizuho Neutral $14 → $18
Mar-24-16Reiterated Mizuho Neutral $16 → $14
Mar-24-16Initiated Northland Capital Outperform
Mar-10-16Initiated Leerink Partners Outperform $21
Feb-25-16Reiterated Mizuho Buy $19 → $16
Feb-24-16Reiterated WallachBeth Buy $33 → $27
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $26 → $24
Feb-08-16Initiated Piper Jaffray Overweight
Jan-07-16Initiated Mizuho Neutral $19
Dec-03-15Resumed Morgan Stanley Equal-Weight $21
Nov-11-15Upgrade WallachBeth Hold → Buy $33
Nov-11-15Reiterated ROTH Capital Buy $21 → $24
Nov-04-15Initiated Cantor Fitzgerald Buy
Oct-21-15Reiterated RBC Capital Mkts Sector Perform $32 → $26
Jul-30-15Downgrade RBC Capital Mkts Outperform → Sector Perform $26 → $32
Jul-24-15Reiterated WallachBeth Hold $26 → $33
Jul-14-15Reiterated ROTH Capital Buy $28.50 → $33
Jul-18-16 01:34PM  Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent PR Newswire
Jul-15-16 09:05AM  Coverage Initiated on Select Drug Manufacturer Stocks
Jul-07-16 04:24PM  Depomed Downgraded On Weakness In Base Business, Stock Run-Up -8.71%
11:17AM  DepoMed downgraded by UBS
Jul-06-16 08:00AM  Depomed to Present at the Cantor Fitzgerald Healthcare Conference GlobeNewswire
Jun-28-16 08:33AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : June 28, 2016 +5.95%
Jun-24-16 09:45AM  Depomed to call special meeting of shareholders on Oct 28
06:03AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-23-16 04:05PM  Depomed Proposes to Call Special Meeting of Shareholders on October 28, 2016 Following Outcome of NUCYNTA Patent Litigation GlobeNewswire
Jun-14-16 04:00PM  Depomed to Present at the JMP Securities Life Sciences Conference GlobeNewswire
09:07AM  Featured Research Report on Drug Manufacturers Stocks
Jun-02-16 09:30AM  RIMA Senvest Grows Even More Bullish On Top Holdings at Insider Monkey
May-26-16 12:42PM  [$$] Starboard Calls for Depomed Board Overhaul at The Wall Street Journal
12:26PM  Starboard seeks Depomed special shareholder meeting
11:17AM  Depomed Issues Statement in Response to Starboards Press Release GlobeNewswire
10:03AM  Starboard calls for overhaul of Depomed board at MarketWatch
09:52AM  StarBoard requests Depomed special shareholder meeting Reuters
09:08AM  Starboard Delivers Letter to Depomed Shareholders PR Newswire
May-25-16 08:55AM  Top Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Nokia, CSC, HPE, Monsanto, Noble Energy, Western Digital and More at 24/7 Wall St.
May-23-16 08:05AM  10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls at 24/7 Wall St.
08:00AM  Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Deterrent Potential and a Favorable Respiratory Profile GlobeNewswire
May-20-16 04:28PM  DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events
May-18-16 04:45PM  Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA Litigation GlobeNewswire
May-16-16 08:00AM  Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain Congress GlobeNewswire
May-14-16 01:04PM  DEPOMED INC Financials
May-10-16 07:08PM  IBB: Makes Small Comeback Following a Tumble Last Week
06:00AM  'Mad Money' Lightning Round: I'm Sticking With at TheStreet
May-09-16 05:30PM  Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade +15.09%
05:30PM  Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade at Investor's Business Daily
03:23PM  Wall Street struggles for gains as crude falls Yahoo Finance
02:58PM  Why These Five Stocks Are in Spotlight Today? at Insider Monkey
10:49AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2016 By the Numbers
07:58AM  Early movers: HCP, LC, TSN, LUV, TEVA, BRKB, DIS TWTR, FB & more at CNBC
07:58AM  Early movers: HCP, LC, TSN, LUV, TEVA, BRKB, DIS TWTR, FB & more at CNBC
May-06-16 02:45PM  Edited Transcript of DEPO earnings conference call or presentation 5-May-16 8:30pm GMT Thomson Reuters StreetEvents
01:45PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report EDGAR Online
May-05-16 07:40PM  How To Follow The Best Activist Investor In The Business at Forbes
05:34PM  Depomed reports 1Q loss AP
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:21PM  Depomed (DEPO) Stock Slumps in After-Hours Trading on Q1 Earnings Miss at TheStreet
04:13PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:00PM  Depomed Reports First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Depomed Inc Earnings Release - After Market Close CCBN
May-04-16 06:26PM  TABLE-Hedge fund managers' investment picks from Sohn conference Reuters
06:06PM  Sohn Conference: Jeff Smith Pitches Depomed (DEPO), Westrock (WRK) at Insider Monkey
04:24PM  Jeffrey Smith Says It's Time to Buy Depomed and WestRock: Sohn 2016 at TheStreet
02:40PM  Starboard's Smith targeting pharma firm for proxy fight at CNBC
12:40PM  What Caused DepoMed's Shares to Skyrocket 20.9% In April at Motley Fool
May-03-16 08:00AM  Depomed to Present at Healthcare Conferences in May GlobeNewswire
Apr-28-16 08:00AM  Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016 GlobeNewswire +5.13%
Apr-27-16 12:16PM  4 Bargain Stocks You Can Buy Today at Motley Fool
12:11PM  Sohn Preview: Starboard Value Adds Infoblox to Already Full Plate at TheStreet
Apr-25-16 12:42PM  [$$] Depomed Says Starboard Has Month to Call Shareholder Meeting at The Wall Street Journal
11:02AM  Depomed gives Starboard chance for meeting to replace board AP
07:54AM  Depomed says Starboard has a month to request for shareholder meeting Reuters
07:01AM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
06:30AM  Depomed Announces Record Date to Determine Shareholders Entitled to Request Special Meeting GlobeNewswire
Apr-19-16 12:24PM  Why This Hedge Fund Activist Wants to Replace Yahoos Entire Board at Fortune
Apr-18-16 03:00PM  Activist shareholder: Board change 'required' at East Bay drug company at
Apr-16-16 08:58PM  Depomed Inc (DEPO): Starboard Value Snatches Up Another 1.5 Million Shares at Insider Monkey
Apr-15-16 02:03PM  Activist Investor Reaffirms Stance On Depomed, Says 'Meaningful Change Is Needed'
12:10PM  East Bay drug company avoids 'distracting' shareholder fight by withdrawing reincorporation plan at
10:43AM  [$$] Starboard to Continue Proxy Fight Against Depomed at The Wall Street Journal
10:15AM  Starboard presses on with push to replace Depomed's board
09:40AM  Stocks to Watch: Citigroup, Mitel Networks, Bats Global at The Wall Street Journal
07:56AM  Starboard says to continue to push for board change at Depomed
07:15AM  Starboard Comments On Depomed's Decision To Withdraw Its Reincorporation Proposal PR Newswire
Apr-14-16 07:20PM  After Hours: Apple App Store Changes, Valeant Mulls Options, BATS IPO
06:33PM  [$$] Depomed Abandons Plans to Reincoporate in Delaware at The Wall Street Journal
05:38PM  Depomed not to reincorporate to Delaware from California
04:56PM  Depomed Announces Decision Not To Pursue Proposed Reincorporation PR Newswire
09:45AM  Why You Should Pay Attention to Activist Jeff Smiths Latest Moves at Insider Monkey
Apr-13-16 08:06PM  [$$] Depomed Faces an Uphill Slog on Starboard Campaign at The Wall Street Journal
Apr-12-16 04:01PM  Why One Activist Thinks This Company Is Too Cheap at Motley Fool
10:37AM  Dealpolitik: Starboard Campaign Is Bitter Pill for Depomed at The Wall Street Journal
Apr-11-16 04:15PM  A Look Into Jeff Smith, John Paulson & Two Other Investors Latest Moves at Insider Monkey
08:11AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : April 11, 2016
12:18AM  [$$] Business Watch at The Wall Street Journal
Apr-08-16 06:01PM  East Bay drug company pushed again to sell this time from the inside at +13.00%
05:08PM  Starboard attempts a coup at Depomed
02:32PM  Depomed Responds To Activist Investor, Notes Starboard Has Made No Contact With Management
02:06PM  Starboard Value Takes Aim at a New Activist Target, Plus All the Details on 3 Other Filings at Insider Monkey
12:23PM  Activist Sinks Teeth Into Depomed, Send Shares Soaring 12% Today at Motley Fool
11:06AM  Starboard urges Depomed board to pursue a potential sale
11:05AM  Egregious Depomed Soars After Activist Starboard Targets Drugmaker
10:43AM  Starboard says Depomed should consider selling itself at MarketWatch
10:15AM  [$$] Starboard Says Depomed Should Consider Selling Itself at The Wall Street Journal
10:05AM  Why Depomed Is Rising on Activist Pressure at 24/7 Wall St.
09:53AM  DepoMed's stock soars on heavy volume after Starboard discloses stake at MarketWatch
09:26AM  Deals of the Day: Vivendi Eyes Mediaset, Starboard Targets DepoMed at The Wall Street Journal
09:06AM  Depomed Issues Statement in Response to Starboard Value LP 13D Filing PR Newswire
08:59AM  DepoMed (DEPO) Stock Surging as Starboard Takes Stake at TheStreet
08:01AM  Starboard Delivers Letter to Depomed CEO and Board of Directors PR Newswire
07:46AM  Early movers: YHOO, ULTA, CBS, LNKD, MET & more at CNBC
12:46AM  PRESS DIGEST- New York Times business news - April 8 Reuters
Apr-07-16 06:08PM  Depomed Activist Starboard Value Seeking Control of Board at Bloomberg
06:07PM  Depomed jumps after activist investor Starboard Value takes stake at MarketWatch
Apr-04-16 04:08PM  DEPOMED INC Files SEC form 8-K, Other Events
04:00PM  Depomed Announces Prepayment of $100 Million of Secured Debt Facility GlobeNewswire
10:55AM  Key Analyst Sees Huge Catalyst in Depomed Patent Suit at 24/7 Wall St.
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology; and Cebranopadol, a molecule for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSenior VP, BDMay 23Sale20.0015,000300,000109,297May 25 04:46 PM
Vargas Thadd MSenior VP, BDMay 10Sale17.6415,000264,600124,297May 10 05:14 PM
Moretti August JChief Financial Officer & SVPMay 09Sale18.005,00090,00022,879May 09 04:48 PM
Schoeneck James APresident and CEOMar 18Option Exercise3.9430,483120,09436,848Mar 21 04:17 PM
Vargas Thadd MSenior VP, BDMar 11Sale16.0023,000368,000137,737Mar 11 06:40 PM
Vargas Thadd MSVP, Business DevelopmentMar 02Sale15.1810,000151,780160,737Mar 04 08:28 PM
Vargas Thadd MSVP, Business DevelopmentJan 11Option Exercise7.1218,180129,442170,737Jan 12 07:10 PM
Schoeneck James APresident and CEODec 28Option Exercise6.116,36538,8906,365Dec 28 07:24 PM
Moretti August JChief Financial Officer & SVPDec 16Option Exercise5.355,00026,75026,319Dec 17 12:31 PM
Moretti August JChief Financial Officer & SVPDec 03Sale18.1115,000271,59721,319Dec 03 06:32 PM
Schoeneck James APresident and CEOSep 29Option Exercise6.4263,561408,15863,561Sep 29 07:24 PM